GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Phase 2

Completed

Conditions: Haemophilus Influenzae Type b
Neisseria Meningitidis

Interventions: Biological: Hib-MenCY-TT vaccine (MenHibrix)
Biological: Meningitec®
Biological: ActHIB®
Biological: Prevenar®
Biological: Infanrix® Penta
Biological: Mencevax® ACWY
Biological: PRP (Polyribosyl Ribitol Phosphate)

First Posted Date: 2005-08-09

Last Posted Date: 2018-08-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 409

Registration Number: NCT00127855

Locations: 🇦🇺
GSK Investigational Site, Subiaco, Western Australia, Australia

Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients

Phase 3

Completed

Conditions: Varicella

Interventions: Procedure: Collection of clinical samples

First Posted Date: 2005-08-08

Last Posted Date: 2019-02-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT00127608

Locations: 🇨🇿
GSK Investigational Site, Praha 8, Czechia

Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Phase 4

Completed

Conditions: Mumps
Rubella
Measles
Varicella

First Posted Date: 2005-08-05

Last Posted Date: 2016-09-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1439

Registration Number: NCT00126997

Locations: 🇵🇱
GSK Investigational Site, Trzebnica, Poland

Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs

Phase 2

Completed

Conditions: Infections, Meningococcal

First Posted Date: 2005-08-05

Last Posted Date: 2016-09-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 125

Registration Number: NCT00126945

Locations: 🇩🇰
GSK Investigational Site, Aarhus N, Denmark

Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine

Phase 2

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: Conjugated meningococcal ACWY-TT (vaccine)
Biological: DTPa/Hib containing vaccine
Biological: Meningitec
Biological: Mencevax ACWY